Zheng Wen-Jing, Xu Yang, Tan Hui, Chen Shu-Guang, Wang Peng-Xiang, Sun Hai-Xiang, Li Rui-Zhe, Zeng Hai-Ying, Zhong Yu-Chen, Cheng Jian-Wen, Fan Jia, Zhou Jian, Shi Hongcheng, Yang Xin-Rong
Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, PR China.
Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, PR China.
Liver Cancer. 2025 Mar 5:1-21. doi: 10.1159/000544966.
In addition to radical resection, liver transplantation (LTx) is an effective treatment for hepatocellular carcinoma (HCC). However, tumor recurrence limits the efficacy of LTx in some patients. This study investigated the role of F-fludeoxyglucose (F-FDG) positron emission tomography/computed tomography (PET/CT) in predicting the prognosis of patients with HCC after LTx.
A total of 278 consecutive patients with HCC who underwent pre-LTx PET/CT were divided into derivation ( = 178) and temporal validation ( = 100) cohorts and evaluated for PET/CT values, immunohistochemical (IHC) findings, and DNA sequencing of tumor tissues.
Patients with post-LTx recurrence exhibited significantly higher tumor maximum standardized uptake values (SUVmax) in pre-LTx PET/CT scans. Receiver operating characteristic curve analyses identified the tumor SUVmax to liver SUVmax ratio (T/L) as the strongest predictor of post-LTx recurrence, with an optimal cutoff value of 1.43. Kaplan-Meier analyses demonstrated that a T/L >1.43 was associated with a shorter time to recurrence (TTR) and overall survival (OS) in both cohorts ( < 0.001 for both). Multivariate Cox regression analyses confirmed that T/L >1.43 was an independent risk factor for tumor recurrence in both cohorts. IHC revealed that T/L >1.43 correlated with higher Ki-67 and CK19 expression. DNA sequencing indicated that tumors with T/L >1.43 had more mutations and a higher TMB. Furthermore, T/L >1.43 was significantly associated with mutations in , , , , , , , and FCGR family genes, as well as TP53 and PI3K signaling-related alterations.
The preoperative T/L is a potential predictor of tumor recurrence in patients with HCC following LTx. Its use improves candidate selection and post-LTx management.
除根治性切除外,肝移植(LTx)是肝细胞癌(HCC)的一种有效治疗方法。然而,肿瘤复发限制了肝移植在某些患者中的疗效。本研究调查了氟代脱氧葡萄糖(F-FDG)正电子发射断层扫描/计算机断层扫描(PET/CT)在预测肝移植术后HCC患者预后中的作用。
共有278例连续接受肝移植术前PET/CT检查的HCC患者被分为推导队列(n = 178)和时间验证队列(n = 100),并对PET/CT值、免疫组化(IHC)结果和肿瘤组织的DNA测序进行评估。
肝移植术后复发的患者在肝移植术前PET/CT扫描中表现出显著更高的肿瘤最大标准化摄取值(SUVmax)。受试者工作特征曲线分析确定肿瘤SUVmax与肝脏SUVmax比值(T/L)是肝移植术后复发的最强预测指标,最佳截断值为1.43。Kaplan-Meier分析表明,T/L>1.43与两个队列中较短的复发时间(TTR)和总生存期(OS)相关(两者均P<0.001)。多变量Cox回归分析证实,T/L>1.43是两个队列中肿瘤复发的独立危险因素。免疫组化显示,T/L>1.43与较高的Ki-67和CK19表达相关。DNA测序表明,T/L>1.43的肿瘤具有更多的突变和更高的肿瘤突变负荷(TMB)。此外,T/L>1.43与CTNNB1、AXIN1、ARID1A、PTPN11、FBXW7、KEAP1、NRAS和FCGR家族基因的突变以及TP53和PI3K信号相关改变显著相关。
术前T/L是肝移植术后HCC患者肿瘤复发的潜在预测指标。其应用可改善候选者选择和肝移植术后管理。